PTEN Phosphohydrolase

• 

  Subject Areas on Research

  • A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN. 
  • A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression. 
  • A sensitized genetic system for the analysis of murine B lymphocyte signal transduction pathways dependent on Bruton's tyrosine kinase. 
  • AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. 
  • Absence of PTEN germ-line mutations in men with a potential inherited predisposition to prostate cancer. 
  • Adenovirus-mediated intraarterial delivery of PTEN inhibits neointimal hyperplasia. 
  • Alkylation of the tumor suppressor PTEN activates Akt and β-catenin signaling: a mechanism linking inflammation and oxidative stress with cancer. 
  • An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. 
  • Autocrine prolactin induced by the Pten-Akt pathway is required for lactation initiation and provides a direct link between the Akt and Stat5 pathways. 
  • Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. 
  • Cell-autonomous activation of the PI3-kinase pathway initiates endometrial cancer from adult uterine epithelium. 
  • Chemerin suppresses hepatocellular carcinoma metastasis through CMKLR1-PTEN-Akt axis. 
  • Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. 
  • Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response? 
  • Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability. 
  • Cytoplasmic polyadenylation element binding protein deficiency stimulates PTEN and Stat3 mRNA translation and induces hepatic insulin resistance. 
  • DAF-18/PTEN inhibits germline zygotic gene activation during primordial germ cell quiescence. 
  • DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. 
  • Detecting Germline PTEN Mutations Among At-Risk Patients With Cancer: An Age- and Sex-Specific Cost-Effectiveness Analysis. 
  • Diffusion-limited phase separation in eukaryotic chemotaxis. 
  • Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells. 
  • Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms. 
  • EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. 
  • Epidermal growth factor receptor signaling pathway is frequently altered in ampullary carcinoma at protein and genetic levels. 
  • Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas. 
  • Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. 
  • Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer. 
  • Gene expression profiling and genetic markers in glioblastoma survival. 
  • Genetic analysis of daf-18/PTEN missense mutants for starvation resistance and developmental regulation during Caenorhabditis elegans L1 arrest. 
  • Genotypic analysis of tumor suppressor genes PTEN/MMAC1 and p53 in head and neck squamous cell carcinomas. 
  • Germline PTEN mutation Cowden syndrome: an underappreciated form of hereditary kidney cancer. 
  • Germline PTEN mutations as a cause of early-onset endometrial cancer. 
  • Glioblastoma multiforme and the epidermal growth factor receptor. 
  • Gorlin syndrome and desmoplastic medulloblastoma: Report of 3 cases with unfavorable clinical course and novel mutations. 
  • Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. 
  • Hemimegalencephaly with Bannayan-Riley-Ruvalcaba syndrome. 
  • Hypo-CpG methylation controls PTEN expression and cell apoptosis in irradiated lung. 
  • Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. 
  • Impact of age at diagnosis on racial disparities in endometrial cancer patients. 
  • In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes. 
  • Inactivation of the tumour suppressor, PTEN, in smooth muscle promotes a pro-inflammatory phenotype and enhances neointima formation. 
  • Increased prevalence of eosinophilic gastrointestinal disorders in pediatric PTEN hamartoma tumor syndromes. 
  • Inducible and cardiac specific PTEN inactivation protects ischemia/reperfusion injury. 
  • Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis. 
  • Inhibition of vascular smooth muscle cell proliferation, migration, and survival by the tumor suppressor protein PTEN. 
  • Interneuron Transplantation Rescues Social Behavior Deficits without Restoring Wild-Type Physiology in a Mouse Model of Autism with Excessive Synaptic Inhibition. 
  • Interplay between c-Src and the APC/C co-activator Cdh1 regulates mammary tumorigenesis. 
  • LncRNAs-directed PTEN enzymatic switch governs epithelial-mesenchymal transition. 
  • Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. 
  • Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma. 
  • Loss of phosphatase and tensin homologue increases transforming growth factor beta-mediated invasion with enhanced SMAD3 transcriptional activity. 
  • Management of reproductive health in Cowden syndrome complicated by endometrial polyps and breast cancer. 
  • Mechanisms of action of rapamycin in gliomas. 
  • Mitochondrial phosphatase PTPMT1 is essential for cardiolipin biosynthesis. 
  • Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. 
  • Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. 
  • Molecular pathogenesis of malignant gliomas. 
  • Mosaic partial deletion of the PTEN gene in a patient with Cowden syndrome. 
  • Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. 
  • Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers. 
  • Mutational analysis of the PTEN gene in human uterine sarcomas. 
  • Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. 
  • Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10). 
  • PI-3 kinase-PTEN signaling node: an intercept point for the control of angiogenesis. 
  • PI3K/Akt and apoptosis: size matters. 
  • PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. 
  • PTEN as an effector in the signaling of antimigratory G protein-coupled receptor. 
  • PTEN hamartoma tumor syndromes. 
  • PTEN hamartomatous tumor syndromes (PHTS): rare syndromes with great relevance to common cancers and targeted drug development. 
  • PTEN loss in the continuum of common cancers, rare syndromes and mouse models. 
  • PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects. 
  • PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. 
  • PTEN polymorphism (IVS4) is not associated with risk of prostate cancer. 
  • PTEN reconstitution alters glioma responses to c-Met pathway inhibition. 
  • PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression. 
  • Phosphatase and tensin homolog (PTEN) regulates hepatic lipogenesis, microsomal triglyceride transfer protein, and the secretion of apolipoprotein B-containing lipoproteins. 
  • Phosphatase and tensin homologue on chromosome 10 (PTEN) directs prostaglandin E2-mediated fibroblast responses via regulation of E prostanoid 2 receptor expression. 
  • Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases. 
  • Phosphoinositide 3-kinase regulates beta2-adrenergic receptor endocytosis by AP-2 recruitment to the receptor/beta-arrestin complex. 
  • Pills of PTEN? In and out for tumor suppression. 
  • Potential role of PTEN phosphatase in ethanol-impaired survival signaling in the liver. 
  • Precision Medicine Approaches When Prostate Cancer Akts Up. 
  • Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. 
  • Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay. 
  • Protein patterns and proteins that identify subtypes of glioblastoma multiforme. 
  • Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. 
  • Pten-null tumors cohabiting the same lung display differential AKT activation and sensitivity to dietary restriction. 
  • Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers. 
  • Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway. 
  • Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes. 
  • Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer. 
  • Sparstolonin B (SsnB) attenuates liver fibrosis via a parallel conjugate pathway involving P53-P21 axis, TGF-beta signaling and focal adhesion that is TLR4 dependent. 
  • Sparstolonin B attenuates early liver inflammation in experimental NASH by modulating TLR4 trafficking in lipid rafts via NADPH oxidase activation. 
  • Strain-specific spontaneous and NNK-mediated tumorigenesis in Pten+/- mice. 
  • Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis. 
  • The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. 
  • The DM domain protein DMRT1 is a dose-sensitive regulator of fetal germ cell proliferation and pluripotency. 
  • The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. 
  • The PTEN tumor suppressor gene and its role in lymphoma pathogenesis. 
  • The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers--a study of the National Cancer Institute of Canada Clinical Trials Group. 
  • The comprehensive role of E-cadherin in maintaining prostatic epithelial integrity during oncogenic transformation and tumor progression. 
  • The expression of PTEN is associated with improved prognosis in patients with ampullary adenocarcinoma after pancreaticoduodenectomy. 
  • The functions and regulation of the PTEN tumour suppressor: new modes and prospects. 
  • The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling. 
  • Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression. 
  • Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells. 
  • Tumor Subtype Determines Therapeutic Response to Chimeric Polypeptide Nanoparticle-based Chemotherapy in Pten-deleted Mouse Models of Sarcoma. 
  • Tumor suppressor MMAC/PTEN inhibits cytokine-induced NFkappaB activation without interfering with the IkappaB degradation pathway. 
  • Twenty-year survival in glioblastoma: a case report and molecular profile. 
  • Up-regulating sphingosine 1-phosphate receptor-2 signaling impairs chemotactic, wound-healing, and morphogenetic responses in senescent endothelial cells. 
  • Utility of EGFR and PTEN numerical aberrations in the evaluation of diffusely infiltrating astrocytomas. Laboratory investigation. 
  • VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling. 
  • Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. 
  • [Cowden disease]. 
  • miR-17-92 cluster targets phosphatase and tensin homology and Ikaros Family Zinc Finger 4 to promote TH17-mediated inflammation. 
  • miR-19 is a key oncogenic component of mir-17-92. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Chen, Ming, Associate Professor in Pathology, Cell Biology
  • Ciofani, Maria, Associate Professor of Integrative Immunobiology, Cell Biology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Muh, Carrie Rebecca, Adjunct Assistant Professor in the Department of Neurosurgery, Neurosurgery